Statins and familial hypercholesterolaemia.

Statins and familial hypercholesterolaemia.

Opis bibliograficzny
Główni autorzy:	Neil, A, Humphries, SE
Format:	Journal article
Język:	English
Wydane:	2009

Podobne zapisy

Effect of statin treatment for familial hypercholesterolaemia on life assurance: results of consecutive surveys in 1990 and 2002.
od: Neil, H, i wsp.
Wydane: (2004)

Controversies in familial hypercholesterolaemia: recommendations of the NICE Guideline Development Group for the identification and management of familial hypercholesterolaemia.
od: Minhas, R, i wsp.
Wydane: (2009)

Cost-effectiveness analysis of the use of a high-intensity statin compared to a low-intensity statin in the management of patients with familial hypercholesterolaemia.
od: Nherera, L, i wsp.
Wydane: (2010)

CURRENT STATIN TREATMENT OF PATIENTS WITH FAMILIAL HYPERCHOLESTEROLAEMIA (FH): RESULTS FROM THE ROYAL COLLEGE OF PHYSICIANS UK NATIONAL AUDIT
od: Seed, M, i wsp.
Wydane: (2011)

Screening for hypercholesterolaemia versus case finding for familial hypercholesterolaemia: a systematic review and cost-effectiveness analysis.
od: Marks, D, i wsp.
Wydane: (2000)

A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia.
od: Marks, D, i wsp.
Wydane: (2003)

Screening for hypercholesterolaemia versus case finding for familial hypercholesterolaemia: a systematic review and cost-effectiveness analysis.
od: Marks, i wsp.
Wydane: (2000-01-01)

Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study.
od: Neil, A, i wsp.
Wydane: (2008)

Extent of underdiagnosis of familial hypercholesterolaemia in routine practice: prospective registry study.
od: Neil, H, i wsp.
Wydane: (2000)

Cost effectiveness analysis of different approaches of screening for familial hypercholesterolaemia.
od: Marks, D, i wsp.
Wydane: (2002)

Cascade screening for familial hypercholesterolaemia: implications of a pilot study for national screening programmes.
od: Marks, D, i wsp.
Wydane: (2006)

Statin treatment for children and adolescents with heterozygous familial hypercholesterolaemia: a systematic review and meta-analysis.
od: Arambepola, C, i wsp.
Wydane: (2007)

Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study
od: Neil, A, i wsp.
Wydane: (2008)

Familial hypercholesterolaemia.
od: Gill, P, i wsp.
Wydane: (2012)

Comparing costs and benefits over a 10 year period of strategies for familial hypercholesterolaemia screening.
od: Marks, D, i wsp.
Wydane: (2003)

The utility of DNA-based testing in patients with familial hypercholesterolaemia in the UK
od: Humphries, SE, i wsp.
Wydane: (2005)

Familial hypercholesterolaemia
od: D.J. Blom
Wydane: (2011-01-01)

Established and emerging coronary risk factors in patients with heterozygous familial hypercholesterolaemia.
od: Neil, H, i wsp.
Wydane: (2004)

Established and emerging coronary risk factors in patients with heterozygous familial hypercholesterolaemia
od: Neil, H, i wsp.
Wydane: (2003)

Development of a high-resolution melting method for mutation detection in familial hypercholesterolaemia patients.
od: Whittall, R, i wsp.
Wydane: (2010)

Effect of statin treatment for familial hypercholesterolaemia on life assurance: results of consecutive surveys in 1990 and 2002
Wydane: (2004)

Established and emerging coronary risk factors in patients with heterozygous familial hypercholesterolaemia
od: Neil, A, i wsp.
Wydane: (2003)

EASILY MISSED? Familial hypercholesterolaemia
od: Gill, P, i wsp.
Wydane: (2012)

Statin treatment and LDL-cholesterol treatment goal attainment among individuals with familial hypercholesterolaemia in primary care
od: Joe Kai, i wsp.
Wydane: (2021-12-01)

NOVEL INFLAMMATORY RISK MARKERS INCLUDING LPPLA2 AND RISK OF CHD IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLAEMIA (FH)
od: Seed, M, i wsp.
Wydane: (2009)

Comparison of the risk of fatal coronary heart disease in treated xanthomatous and non-xanthomatous heterozygous familial hypercholesterolaemia: a prospective registry study.
od: Neil, H, i wsp.
Wydane: (2003)

Non-coronary heart disease mortality and risk of fatal cancer in patients with treated heterozygous familial hypercholesterolaemia: a prospective registry study.
od: Neil, H, i wsp.
Wydane: (2005)

NOVEL INFLAMMATORY RISK MARKERS INCLUDING LPPLA2 AND RISK OF CHD IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLAEMIA (FH)
od: Seed, M, i wsp.
Wydane: (2009)

How many individuals with Familial Hypercholesterolaemia (FH) need to be identified to achieve the NHS 2019 Long Term Plan ambition?
od: S.E. Humphries, i wsp.
Wydane: (2023-12-01)

Modelling a two-stage screen for autosomal dominant familial hypercholesterolaemia (FH) in UK Biobank
od: J. Gratton, i wsp.
Wydane: (2022-10-01)

Identification of FH-causing variants in patients with clinical familial hypercholesterolaemia recruited into the 100,000 genome project: preliminary analysis
od: A. Rimbert, i wsp.
Wydane: (2021-09-01)

Familial Hypercholesterolaemia: An Updated Overall Management
od: Mohd Kasim, Noor Alicezah, i wsp.
Wydane: (2020)

Analysis of the frequency and spectrum of mutations recognised to cause familial hypercholesterolaemia in routine clinical practice in a UK specialist hospital lipid clinic
od: Futema, M, i wsp.
Wydane: (2013)

Analysis of the frequency and spectrum of mutations recognised to cause familial hypercholesterolaemia in routine clinical practice in a UK specialist hospital lipid clinic.
od: Futema, M, i wsp.
Wydane: (2013)

Genetic causes of familial hypercholesterolaemia in patients in the UK: relation to plasma lipid levels and coronary heart disease risk.
od: Humphries, SE, i wsp.
Wydane: (2006)

Prevalence of familial hypercholesterolaemia (FH)-causing variants and impact on LDL-C concentration in European, South Asian, and African ancestry groups of the UK Biobank
od: J. Gratton, i wsp.
Wydane: (2023-12-01)

Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)
od: Vallejo-Vaz, Antonio J., i wsp.
Wydane: (2020)

Novel molecular therapies for the treatment of familial hypercholesterolaemia
od: Kerr, A
Wydane: (2016)

Development of sensitive and specific age- and gender-specific low-density lipoprotein cholesterol cutoffs for diagnosis of first-degree relatives with familial hypercholesterolaemia in cascade testing.
od: Starr, B, i wsp.
Wydane: (2008)

Familial Hypercholesterolaemia as a Predisposing Factor for Atherosclerosis
od: Anastasia V. Poznyak, i wsp.
Wydane: (2022-10-01)